BACKGROUND AND PURPOSE: We have recently reported the safety of intraventricular @entity1854 for the treatment of @entity2806 from @entity2553 . Treatments have been accompanied previously by cerebral angiography to gauge treatment effect on established @entity2553 . We presently report the safe coadministration of intraventricular @entity1854 and @entity8962 in 10 @entity1 with secured @entity1756 in the intensive care unit, without the use of cerebral angiography for @entity2553 treatment. METHODS: @entity1 were considered eligible for treatment on the basis of @entity510 grade or manifestation of @entity2553 by either transcranial Doppler ultrasonography (TCD) or neurological examination criteria. The route of administration was intraventricular, by way of ventriculostomy. Two separate protocols differing in dosage frequency were used, depending on the presence or absence of a new @entity51 . Response to treatment was measured by TCD and @entity16 . RESULTS: Good outcome was observed in 7 of 8 @entity2553 @entity1 presenting with clinical @entity510 grade > or =3. Four @entity1 demonstrated reversal of well-defined @entity51 ( @entity1269 , paraparesis) in the setting of treatment. Seven @entity1 demonstrated a decrease in TCD velocities within 1 hour of treatment. Two @entity1 died: 1 from intractable @entity2553 despite maximal medical management and angioplasty and 1 from pulmonary causes. One episode of @entity551 occurred in the setting of a high dose of medication. This responded promptly to medical management. @entity428 did not occur; modest elevations of both intracranial pressure and mean arterial blood pressure were observed when @entity390 and @entity391 were associated with treatment, which occurred commonly in awake subjects. CONCLUSIONS: Intraventricular @entity1854 with @entity8962 may be safely administered in the intensive care unit setting without the requirement of cerebral angiography to guide the effects of therapy.

Safety of intraventricular @entity1854 and XXXX for the treatment of @entity2553 in the intensive care unit setting.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity8962 :: ('CHEBI:26977', 'Chemical') :: ['thiosulfate'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity2806 :: ('MESH:D002545', 'Disease') :: ['cerebral ischemia'] @entity510 :: ('MESH:D013345', 'Disease') :: ['subarachnoid hemorrhage'] @entity1269 :: ('MESH:D010291', 'Disease') :: ['hemiparesis'] @entity428 :: ('MESH:D019586', 'Disease') :: ['Prolonged intracranial hypertension'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological criteria'] @entity1854 :: ('MESH:D009599', 'Chemical') :: ['sodium nitroprusside'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficits', 'neurological deficit'] @entity2553 :: ('MESH:D020301', 'Disease') :: ['cerebral vasospasm', 'vasospasm'] @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension'] @entity1756 :: ('MESH:D017542', 'Disease') :: ['ruptured cerebral aneurysms']
@entity8962 :: (CHEBI:26977,Chemical) :: ['thiosulfate']
